This was a prospective physiological study in adult women with type 1 diabetes using standardized testing across the menstrual cycle. Researchers followed participants through one or more full cycles, confirming ovulation and timing with hormone and/or cycle tracking methods. Insulin sensitivity was measured repeatedly (e.g., using clamp or validated modeling approaches) at defined phases: early follicular, peri‑ovulatory, and luteal. Primary outcomes were changes in insulin sensitivity and glucose control measures between phases.
Insulin sensitivity was highest in the follicular phase (earlier in the cycle) and decreased in the mid‑ to late‑luteal phase, indicating increased insulin resistance as progesterone levels rose. Around ovulation, some women showed intermediate changes, reinforcing that sex hormones modulate insulin action. These shifts were statistically significant at the group level, but individual responses varied widely, with some women showing minimal change and others showing marked shifts. The study also noted that changes in insulin needs across the cycle could not be fully explained by diet or activity alone, highlighting a direct hormonal effect.
The sample size was modest and limited to women with established type 1 diabetes, so results may not apply to all ages, ethnicities, or those with type 2 or no diabetes. Study conditions were controlled and may not fully reflect daily variability in stress, sleep, diet, or exercise. Hormone levels and ovulation timing were carefully tracked, but there can still be misclassification of exact phase, especially in irregular cycles. The strong group‑level trends may not predict any one individual’s pattern, so using these findings as a rigid dosing template would be unsafe; insulin changes must be supervised. Funding sources and potential conflicts were reported in the original article and should be reviewed to fully assess bias.
This study strengthens evidence that menstrual cycle hormones meaningfully affect insulin sensitivity in type 1 diabetes, particularly as progesterone rises after ovulation. Methodologically, repeated measures within the same women and standardized assessment of insulin sensitivity are notable strengths, though the controlled setting may differ from daily life. The findings align with prior smaller studies and clinical observations of higher glucose levels premenstrually, but they highlight large person‑to‑person variation, underscoring the need for individualized patterns rather than fixed “rules.” For restorative practice, it supports integrating detailed cycle charting with glycemic data to uncover each woman's pattern rather than assuming a uniform luteal‑phase insulin increase.
Encourage women with type 1 diabetes to chart both their menstrual cycles and glucose/insulin data together (including ovulation indicators when possible). Look for recurring patterns such as rising glucose or higher insulin needs in the days after ovulation and especially in the week before bleeding. Discuss with a clinician whether phased insulin adjustments (e.g., basal or bolus changes in predictable luteal days) might be appropriate, based on each woman’s documented pattern. Integrate other root‑cause factors—sleep, stress, inflammation, thyroid, and nutrition—that can magnify hormone‑related insulin resistance, and reassess regularly as cycles or life circumstances change.
For women with type 1 diabetes, this study confirms that your insulin needs can change with your cycle, especially after you ovulate and in the week or so before your period. Rising hormones like progesterone can make your body a bit more resistant to insulin, which may show up as higher blood sugars even if you are eating and moving the same. Not every woman has the same pattern, so your changes may be bigger, smaller, or shifted in time compared with others. Tracking your cycle days (and ovulation if possible) alongside your glucose readings can help you and your clinician see your unique pattern and look for root causes like inflammation, stress, thyroid issues, or nutrient gaps that might worsen these swings.
Expect, on average, reduced insulin sensitivity in the mid‑ to late‑luteal phase in women with type 1 diabetes, though inter‑individual variability is high. Pair detailed cycle charting (bleeding patterns, cervical mucus, ovulation tests/BBT where feasible) with CGM and insulin dosing logs to identify patient‑specific patterns in insulin needs by phase. Consider structured experiments over 2–3 cycles: maintain stable diet and activity where realistic while adjusting basal and/or bolus ratios in a phased manner (e.g., small, supervised increases post‑ovulation) guided by CGM trends. From a restorative lens, evaluate for contributors that may amplify luteal‑phase resistance—subclinical hypothyroidism, hyperandrogenism/PCOS phenotypes, micronutrient deficiencies (vitamin D, magnesium), chronic inflammation (CRP), and sleep or mood disorders. Document which biomarkers change with cycle phase (estradiol, progesterone, LH, fasting insulin/C‑peptide where present, CRP) to better understand each woman’s hormonal‑metabolic profile and to integrate insulin adjustments with broader menstrual and fertility care plans.
Educational insights, not a diagnosis or individualized treatment advice. Discuss findings with your own clinician. Visit Reproductive Health Insights to explore fertility resources.